The report on the global continuous blood glucose monitoring systems market provides qualitative and quantitative analysis for the period from 2021-2030. The global continuous glucose monitoring systems market was valued at USD 7.81 billion in 2022 and is expected to reach USD 11.44 billion in 2030, with a CAGR of 4.27% during the forecast period 2023-2030. The study on continuous blood glucose monitoring systems market covers the analysis of the leading geographies such as North America, Europe, Asia Pacific, and RoW for the period of 2021-2030.
Continuous Glucose Monitoring (CGM) is a specialized segment within the broader Blood Glucose Monitoring Systems market. It offers a more advanced approach to tracking an individual's blood glucose levels in real-time. Unlike traditional glucose meters that provide single measurements at specific moments, CGM systems use sensors inserted under the skin to continuously monitor glucose levels in the interstitial fluid. These sensors transmit data continuously to a receiver or a smartphone application, enabling users to identify patterns and trends in their glucose levels. This real-time information is crucial for reducing the risk of severe hypoglycemia or hyperglycemia and improving overall control of blood sugar levels. CGM systems are particularly beneficial for individuals who face challenges in achieving their target glucose levels with intermittent glucose meters.
The growth of the Continuous Blood Glucose Monitoring (CGM) systems market is propelled by the increasing prevalence of diabetes. This upsurge in the diabetic population has generated a heightened demand for efficient and user-friendly tools to track blood glucose levels. CGM systems have emerged as a pivotal solution, providing real-time and comprehensive monitoring, and empowering individuals to make timely adjustments to their dietary choices, medication, and lifestyle. The advantages presented by CGM systems over traditional glucose meters are the primary drivers behind the CGM market's growth. The real-time monitoring capabilities, coupled with a deeper understanding of glucose fluctuations, significantly enhance the appeal of CGM systems. This increased capability equips individuals with diabetes with more comprehensive insights into their condition, enabling proactive adjustments to maintain glycemic control. However, the market may encounter challenges related to CGM system limitations, potential adverse effects, device comfort, accuracy, and cost. Nonetheless, ongoing advancements in sensor technology and wearable devices offer significant opportunities for the continuous blood glucose monitoring systems market. These innovations have the potential to enhance device accuracy, user comfort, and overall accessibility, further fueling market growth.
North America is projected to hold the most prominent market share in the upcoming forecast period. In North America specifically, the United States has one of the highest diabetes prevalence rates worldwide, providing a favorable environment for the Continuous Glucose Monitoring (CGM) market. This is due to its well-established healthcare infrastructure, comprising healthcare providers, hospitals, clinics, and diabetes care specialists. Moreover, many U.S. insurance providers offer coverage and reimbursement for CGM systems, enhancing accessibility for a wider demographic of diabetes patients. This insurance support acts as a catalyst for the adoption of CGM systems, promoting their utilization in the market. The Asia-Pacific (APAC) region is witnessing rapid growth in the CGM market due to the substantial increase in diabetes prevalence, notably in countries like India and China. As the diabetic population continues to expand, the demand for effective glucose monitoring solutions, including CGM systems, rises. This region presents a promising market for the CGM industry.
2. Internal and External subject matter experts
3. Professionals and participants from the industry
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/country managers
5. Vice President level executives.
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies
2. Complete coverage of all the segments in the continuous blood glucose monitoring systems market to analyze the trends, developments in the global market and forecast of market size up to 2030.
3. Comprehensive analysis of the companies operating in the global continuous blood glucose monitoring systems market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. The Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
Continuous Glucose Monitoring (CGM) is a specialized segment within the broader Blood Glucose Monitoring Systems market. It offers a more advanced approach to tracking an individual's blood glucose levels in real-time. Unlike traditional glucose meters that provide single measurements at specific moments, CGM systems use sensors inserted under the skin to continuously monitor glucose levels in the interstitial fluid. These sensors transmit data continuously to a receiver or a smartphone application, enabling users to identify patterns and trends in their glucose levels. This real-time information is crucial for reducing the risk of severe hypoglycemia or hyperglycemia and improving overall control of blood sugar levels. CGM systems are particularly beneficial for individuals who face challenges in achieving their target glucose levels with intermittent glucose meters.
The growth of the Continuous Blood Glucose Monitoring (CGM) systems market is propelled by the increasing prevalence of diabetes. This upsurge in the diabetic population has generated a heightened demand for efficient and user-friendly tools to track blood glucose levels. CGM systems have emerged as a pivotal solution, providing real-time and comprehensive monitoring, and empowering individuals to make timely adjustments to their dietary choices, medication, and lifestyle. The advantages presented by CGM systems over traditional glucose meters are the primary drivers behind the CGM market's growth. The real-time monitoring capabilities, coupled with a deeper understanding of glucose fluctuations, significantly enhance the appeal of CGM systems. This increased capability equips individuals with diabetes with more comprehensive insights into their condition, enabling proactive adjustments to maintain glycemic control. However, the market may encounter challenges related to CGM system limitations, potential adverse effects, device comfort, accuracy, and cost. Nonetheless, ongoing advancements in sensor technology and wearable devices offer significant opportunities for the continuous blood glucose monitoring systems market. These innovations have the potential to enhance device accuracy, user comfort, and overall accessibility, further fueling market growth.
North America is projected to hold the most prominent market share in the upcoming forecast period. In North America specifically, the United States has one of the highest diabetes prevalence rates worldwide, providing a favorable environment for the Continuous Glucose Monitoring (CGM) market. This is due to its well-established healthcare infrastructure, comprising healthcare providers, hospitals, clinics, and diabetes care specialists. Moreover, many U.S. insurance providers offer coverage and reimbursement for CGM systems, enhancing accessibility for a wider demographic of diabetes patients. This insurance support acts as a catalyst for the adoption of CGM systems, promoting their utilization in the market. The Asia-Pacific (APAC) region is witnessing rapid growth in the CGM market due to the substantial increase in diabetes prevalence, notably in countries like India and China. As the diabetic population continues to expand, the demand for effective glucose monitoring solutions, including CGM systems, rises. This region presents a promising market for the CGM industry.
Report Findings
1) Drivers
- The growth of the continuous blood glucose monitoring (CGM) systems market is driven by the growing prevalence of diabetes.
- The advantages offered by CGM systems over traditional glucose meters drive the growth of the CGM market.
2) restraints
- Limitations and potential adverse effects associated with the CGM systems may act as restraining factors.
3) opportunities
- Ongoing advancements in sensor technology and wearable devices are likely to offer prominent opportunities for the continuous blood glucose monitoring systems market.
Research Methodology
A) Primary Research
The primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents.The primary respondents approached include:
1. Key Opinion Leaders2. Internal and External subject matter experts
3. Professionals and participants from the industry
The primary research respondents typically include:
1. Executives working with leading companies in the market under review2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/country managers
5. Vice President level executives.
B) Secondary Research
Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.The secondary sources of the data typically include:
1. Company reports and publications2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies
Segments Covered
The global continuous blood glucose monitoring systems market is segmented on the basis of component, demography, and end user.The Global Continuous Blood Glucose Monitoring Systems Market by Component
- Sensors
- Transmitters
- Receivers
The Global Continuous Blood Glucose Monitoring Systems Market by Demography
- Child Population
- Adult Population
The Global Continuous Blood Glucose Monitoring Systems Market by End User
- Home Healthcare
- Others
Company Profiles
The companies covered in the report include:
- F. Hoffmann-La Roche Ltd
- Senseonics
- Abbott Laboratories
- A. Menarini Diagnostics s.r.l
- Dexcom, Inc.
- Insulet Corporation
- Ypsomed AG
- Medtronic
- Tandem Diabetes Care, Inc.
- Novo Nordisk A/S
What does this Report Deliver?
1. Comprehensive analysis of the global as well as regional markets of the continuous blood glucose monitoring systems market.2. Complete coverage of all the segments in the continuous blood glucose monitoring systems market to analyze the trends, developments in the global market and forecast of market size up to 2030.
3. Comprehensive analysis of the companies operating in the global continuous blood glucose monitoring systems market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. The Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Preface
Chapter 2. Executive Summary
Chapter 3. Global Continuous Blood Glucose Monitoring Systems Market Overview
Chapter 5. Company Profiles and Competitive Landscape
Chapter 6. Global Continuous Blood Glucose Monitoring Systems Market by Component
Chapter 7. Global Continuous Blood Glucose Monitoring Systems Market by Demography
Chapter 8. Global Continuous Blood Glucose Monitoring Systems Market by End User
Chapter 9. Global Continuous Blood Glucose Monitoring Systems Market by Region 2023-2030
Companies Mentioned
- F. Hoffmann-La Roche Ltd
- Senseonics
- Abbott Laboratories
- A. Menarini Diagnostics s.r.l
- Dexcom, Inc.
- Insulet Corporation
- Ypsomed AG
- Medtronic
- Tandem Diabetes Care, Inc.
- Novo Nordisk A/S
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 255 |
| Published | October 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 7.81 Billion |
| Forecasted Market Value ( USD | $ 11.44 Billion |
| Compound Annual Growth Rate | 4.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
